Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8380075 | 0.80 | TSHR (0.31) | TSHRNFKB1CYP2C19 | |
| SCHEMBL819484 | 0.73 | TSHR (0.44) | TSHRNFKB1CYP2C19 | |
| SCHEMBL1120435 | 0.70 | — | — | |
| SCHEMBL22240454 | 0.70 | — | — | |
| SCHEMBL11125649 | 0.68 | TSHR (0.30) | TSHRNFKB1CYP2C19 | |
| Iodide SCHEMBL22031615 | 0.68 | SOS1 (0.52) | SOS1SOS2 | |
| Hydrochloric Acid SCHEMBL3881741 | 0.68 | SOS1 (0.52) | SOS1SOS2TSHR | |
| Hydrochloric Acid SCHEMBL1992388 | 0.68 | SOS1 (0.52) | SOS1SOS2TSHR | |
| Ammonia Solution, Strong SCHEMBL27616014 | 0.68 | SOS1 (0.52) | SOS1SOS2 | |
| Pempidine SCHEMBL4798468 | 0.67 | TSHR (0.58) | TSHRNFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923444-B2 | 1-aryl-alkyl-substituted-1,4-diazepine derivatives; 1-(4-Chloro-3-methoxy-phenyl)-3,3,5,5-tetramethyl-[1,4]diazepane for example; antidepressants, analgesics, various psychological disorders, dementia, eating disorders, drug abuse; side effect reduction | NEUROSEARCH A/S (DK) | 2011-04-12 | — | — | US | disclosed |
| EP-1851207-B1 | ALKYL SUBSTITUTED HOMOPIPERAZINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2009-07-01 | — | — | EP | disclosed |
| US-20080132489-A1 | Novel Alkyl Substituted Homopiperazine Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | ANIONA APS (DK) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132489-A1 | Novel Alkyl Substituted Homopiperazine Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC6A2, SLC18A2, SLC6A4 | SOS1 3664/4885SOS2 2822/4885TSHR 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.